Compound ID | 1958
Synonym(s): ETX-2514 | ETX2514
Class: Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO])
Details of activity: | DBOs bind reversibly to the beta-lactamase in the active site, inhibits class A, C, D and weakly inhibits penicillin binding protein 2 in Enterobacteriaceae |
Combined with other compounds: | Yes |
Description: | Synthetic compound. In clinical development in fixed combination with Sulbactam against Acinetobacter infections. |
Institute where first reported: | Entasis Therapeutics, Innoviva |
Year first mentioned: | 2017 |
Highest developmental phase: | Phase 3 (NCT03894046) |
Development status: | Active (as of 2022) |
Chemical structure(s): | |||||||||||
|
|
External links: | |
PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/89851852 |
Guide to Pharmacology: | durlobactam |
Citation: | https://pubmed.ncbi.nlm.nih.gov/28835096/ |